BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Teva Hong Kong Partners with Kerry Pharma to Enhance Medicine Distribution Across Hong Kong, Macau, and the Greater Bay Area

Teva Hong Kong ("Teva"), has announced a strategic partnership with Kerry Pharma, the subsidiary of Kerry Logistics Network Ltd ("KLN"). Leveraging Ke...

March 17, 2025 | News

Innovent’s SYCUME® Becomes China’s First IGF-1R Antibody Approved for Thyroid Eye Disease

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

March 17, 2025 | News

BioCity Biopharmaceutics and MSD Partner to Evaluate BC3195-KEYTRUDA® Combo in Global Phase 1/2 Trial

BioCity Biopharmaceutics Co., Ltd., a clinical-stage biopharmaceutical company, announced that it has entered into a clinical trial collaboration agr...

March 14, 2025 | News

WuXi XDC and AbTis Partner to Advance Site-Selective ADC Conjugation

WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organiza...

March 12, 2025 | News

Sichuan Kelun-Biotech’s TROP2 ADC Sacituzumab Tirumotecan Secures NMPA Approval for EGFR-Mutant NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP...

March 11, 2025 | News

Gan & Lee Initiates Phase 2 Trial of Bofanglutide, the First GLP-1 Mono-Agonist to Challenge Tirzepatide in Weight Management

Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been successfully dosed in a P...

March 11, 2025 | News

Fosun Pharma’s Foritinib Secures NMPA Nod for ALK+ NSCLC with Strong CNS Control and Improved Safety

Fosun Pharma announced that the National Medical Products Administration (NMPA) has officially accepted the marketing authorization application for Foritin...

March 10, 2025 | News

Everest Medicines Doses First Patient with AI-Driven Personalized mRNA Cancer Vaccine EVM16 in Landmark Clinical Trial

The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest's proprietary AI-based tumor neoan...

March 07, 2025 | News

GenAssist Gains FDA IND Clearance for First-in-Class Base Editing Therapy for Duchenne Muscular Dystrophy

GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company specializing in genome medicines, is thrilled to announce that it has received&n...

March 07, 2025 | News

CStone Pharmaceuticals Doses First Patient in Global Phase I Trial of Trispecific Antibody CS2009

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therap...

March 05, 2025 | News

Raziel Therapeutics Launches Phase 3 Study in China for RZL-012, an Injectable Fat Reduction Treatment

Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phas...

March 05, 2025 | News

WuXi Biologics Introduces EffiX™ a High-Yield E. coli Expression Platform for Recombinant Proteins and Plasmid DNA Production

EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. ...

March 04, 2025 | News

China Fapon Biopharma secures US FDA IND approval for FP008 a first-in-class immunocytokine for resistant solid tumors

Fapon Biopharma, a biotech innovator in developing therapeutic antibodies and fusion proteins, is pleased to announce that the U.S. Food and Drug Administr...

March 03, 2025 | News

Alphamab Oncology and CSPC Dose First Patient in Phase III Trial of JSKN003 for HER2-Positive Breast Cancer

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has...

February 28, 2025 | News

Stay Connected